Research Papers

This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.

Displaying 176 papers

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model

3/2023 - Antimicrobial Agents and Chemotherapy

Author(s): Si-Yang Li, Paul J. Converse, Fabrice Betoudji, Jin Lee, Khisimuzi Mdluli, Anna Upton, Nader Fotouhi, Eric L. Nuermberger

Tags: Bedaquiline (TMC-207), BPaL, Clinical Development, Drug Discovery, Linezolid, Preclinical Data, Preclinical Models, Pretomanid/PA-824

Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience

3/2023 - International Journal of Infectious Diseases

Author(s): Francesca Saluzzo, Juan Espinosa-Pereiro, Stephan Dressler, Ezio Tàvora Dos Santos Filho, Stephanie Seidel, Jesus Gonzalez Moreno, Norbert Heinrich, Adrian Sanchez-Montalva, Daniela Maria Cirillo

Tags: Advocacy, Clinical Development, Community Engagement, Trial Design, Underserved Populations

Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis

11/2022 - PLOS Global Public Health

Author(s): Aastha Gupta, Sandeep Juneja, Suvanand Sahu, Mohammed Yassin, Grania Brigden, Eliud Wandwalo, Saurabh Rane, Fuad Mirzayev, Matteo Zignol

Tags: Bedaquiline (TMC-207), BPaL, Linezolid, Pretomanid/PA-824, TB Burden, TB Drug Market, TB Market

Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

9/2022 - New England Journal of Medicine

Author(s): Francesca Conradie, et al., for the ZeNix Trial Team

Tags: Bedaquiline (TMC-207), BPaL, Clinical Trial Results, Linezolid, MDR-TB, Pretomanid/PA-824, XDR-TB

Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice

7/2022 - International Journal of Toxicity

Author(s): Jeffrey L Ambroso, John Dillberger, Rebecca Bruning-Barry, Tian Yang

Tags: Pretomanid/PA-824

Male reproductive hormones in patients treated with pretomanid

6/2022

Author(s): Boekelheide K, Olugbosi M, Nedelman J, Everitt D, Smith E, Betteridge M, Sun E, Spigelman M

Tags: MDR-TB, Pretomanid/PA-824, XDR-TB

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys

4/2022 - Toxicology Reports

Author(s): Rebecca Bruning-Barry, Jeffrey L.Ambroso, John Dillberger, Tian J.Yang

Tags: Pretomanid/PA-824

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

3/2022 - Antimicrobial Chemotherapy

Author(s): Anna Bateson, Julio Ortiz Canseco, Timothy D McHugh, Adam A Witney, Silke Feuerriegel, Matthias Merker, Thomas A Kohl, Christian Utpatel, Stefan Niemann, Sönke Andres, Katharina Kranzer, Florian P Maurer, et al.

Tags: Drug-Sensitivity Testing, Pretomanid/PA-824

Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects

3/2022 - Antimicrobial Chemotherapy

Author(s): Paul Bruinenberg, Jerry Nedelman, Tian J. Yang, Fran Pappas, Dan Everitt

Tags: Pharmacokinetics, Sutezolid

Budgetary impact of using BPaL for treating extensively drug resistant tuberculosis

1/2022 - BMJ Global Health

Author(s): Christiaan Mulder, Stephan Rupert, Ery Setiawan, Elmira Mambetova, Patience Edo, Jhon Sugiharto, Sani Useni, Shelly Malhotra, Sarah Cook-Scalise, Imran Pambudi, Abdullaat Kadyrov, Adebola Lawanson, Susan van den Hof, et al

Tags: BPaL, MDR-TB, TB Market, XDR-TB

Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis

12/2021 - Antimicrobial Agents and Chemotherapy

Author(s): Deepak Almeida, Paul J. Converse, Si-Yang Li, Anna M. Upton, Nader Fotouhi, and Eric L. Nuermberger

Tags: Bedaquiline (TMC-207), Preclinical Data, Preclinical Models

Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

7/2021 - BMC Public Health

Author(s): S. E. J. van de Berg, P. T. Pelzer, A. J. van der Land, E. Abdrakhmanova, A. Muhammad Ozi, M. Arias, S. Cook-Scalise, G. Dravniece, A. Gebhard, S. Juneja, R. Handayani, D. Kappel, M. Kimerling, I. Koppelaar, S. Malhotra et al

Tags: BPaL, MDR-TB, Regimen Change, TB Drug Market, TB Market, XDR-TB

Pretomanid with Bedaquiline and Linezolid for Drug Resistant TB: A Comparison of Prospective Cohorts

4/2021

Author(s): S. Oelofse, A. Esmail, A. H. Diacon F. Conradie, O. Olayanju, N. Ngubane, P. Howell, D. Everitt, A. M. Crook, C. M. Mendel, G. H. Wills, M. Olugbosi, A. del Parigi, E. Sun, A. Calatroni, M. Spigelman, K. Dheda

Tags: Bedaquiline (TMC-207), Linezolid, MDR-TB, Pretomanid/PA-824

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

3/2021 - International Journal of Tuberculosis and Lung Disease

Author(s): C. D. Tweed, G. H. Wills, A. M. Crook

Tags: Clinical Trial Results, Moxifloxacin, Pretomanid/PA-824, Pyrazinamide, STAND/NC-006

Pages